心肌缺血再灌注损伤的研究进展  

Research progress of myocardial ischemia-reperfusion injury

作　　者：吴晓燕[1] 苗琳[1] 郑蕊[1] 樊官伟[1] 

机构地区：[1]天津中医药大学中医药研究院天津市中药药理学重点实验室,天津300193

出　　处：《中国临床药理学杂志》2016年第11期1043-1045,1056,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家重点基础研究发展计划基金资助项目(2012CB518404);国家自然基金资助项目(81273891)

摘　　要：再灌注是治疗缺血性心脏病的常用措施,但再灌注常导致心律失常、心肌舒缩功能障碍及心肌细胞不可逆损伤加重等并发症的发生,引起心肌缺血再灌注损伤(MIRI)。本文从MIRI的治疗原则和相关药物研究进行综述。Reperfusion is a common therapeutic method of ischemic heart disease. However,reperfusion can cause arrhythmia,myocardial diastole and contraction dysfunction,as well as irreversible injury to myocardial cells and so on, inducing myocardial ischemic reperfusion injury（ MIRI）. In this paper,the author reviewed the research hot spots of MIRI from the aspects of its therapeutic principle and relevant drugs.

关 键 词：心肌缺血 再灌注损伤 心脏病 

分 类 号：R972[医药卫生—药品]